German Biotech's Novel Approach to Heart Disease Just Secured Major Backing

Jan de Vries · 2026-08-28

Here's a story that caught my eye from the European startup scene. A German biotech firm, fresh out of Heidelberg, just launched with a significant financial boost to tackle some of the toughest challenges in heart disease. It's the kind of news that makes you lean in a little closer. Revier Therapeutics has officially kicked off operations, announcing the close of a $6.4 million Seed financing round. That's right, they've secured over six million dollars right out of the gate. The funding was led by the KHAN Technology Transfer Fund II, with key participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. It's not just about the money, though. It's about what they're planning to do with it. ### The Unmet Need in Cardiometabolic Disease Let's talk about the problem they're aiming to solve. Despite all the advances in medicine, millions of patients are still stuck with limited options. We're talking about conditions like heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). These aren't rare—they affect a huge number of people, and the current treatments often don't get to the root of the issue. Prof. Eva van Rooij, the company's co-founder and CEO, put it plainly. She said the next generation of medicines has to go deeper. They need to address the underlying biology that drives the disease itself, not just manage symptoms. That's a much taller order, but it's also where real, long-term solutions for patients are found. ### A First-of-its-Kind Therapeutic Strategy So, how is Revier planning to pull this off? Their big bet is on something called class IIa histone deacetylases, or HDACs. Now, don't let the jargon scare you off. Think of HDACs as specific enzymes in the body that play a key role in how certain severe diseases develop and progress. Here's the innovative part. Earlier attempts to target HDACs were a bit like using a sledgehammer—they hit a broad range of targets, which often led to serious side effects that limited how much medicine a patient could take. Revier's approach is designed to be more like a precision laser. - They've created orally available small molecules. - These molecules are designed to selectively inhibit only the class IIa HDACs that are causing the problem. - The goal is to block the disease-driving activity while leaving the healthy, essential functions completely alone. Prof. Johannes Backs, the scientific founder, explained that this selective targeting is what could make their therapy both effective and safer. It's a first-in-class approach for cardiometabolic diseases. ### Why Investors Are Betting on This Science The confidence from investors speaks volumes. Michael Hamacher from KHAN Technology Transfer Fund II didn't hold back. He said Revier's strategy has the potential to "unlock the therapeutic promise of HDAC biology" in a way previous methods couldn't. He pointed to the exceptional leadership team and deep scientific expertise as key factors, suggesting the company could genuinely reshape the standard of care for patients. ### What's Next for the Fresh Capital? With the $6.4 million in the bank, the plan is clear. The money will fuel the development of their preclinical pipeline, specifically advancing their lead program for HFpEF and a second program for ASCVD. Beyond the lab work, they'll also be building out their operational, scientific, and clinical teams. It's all about moving from promising science to tangible therapies for the clinic. It's a classic startup story, but with a vital twist. This isn't about building another app. It's about translating complex, frontier science into treatments that could change lives. Watching a company like this emerge from Europe's robust research ecosystem, with solid backing and a clear, novel mission, is exactly the kind of development that keeps the biotech sector so exciting.